市場調查報告書
商品編碼
949415

鐮形血球貧血症治療的全球市場:2019-2025年

Sickle Cell Disease Treatment Market 2019-2025

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球鐮形血球貧血症治療市場,預計在預測期間內,以大幅度的年複合成長率成長。促進市場成長的主要原因中,包含醫藥品企業的革新的高漲及各國政府的支援。

本報告提供全球鐮形血球貧血症治療市場相關調查分析,市場概要,市場成長的影響要素,市場規模與預測,各市場區隔的市場分析,各地區、國家的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 報告概要

第2章 市場概要及考察

  • 調查範圍
  • 分析師的考察&目前市場趨勢
  • 規則&法規

第3章 競爭情形

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析
    • Emmaus Life Science, Inc.
    • Bristol-Myers Squibb Co.
    • Pfizer, Inc.
    • Global Blood Therapeutics, Inc
    • Novartis AG

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 全球鐮形血球貧血症治療市場:各類型
    • 投藥
    • 輸血
    • 骨髓移植
  • 全球鐮形血球貧血症治療市場:各疾病類型
    • 鐮狀細胞貧血症
    • 鐮狀血紅素C病
    • 鐮狀β地中海型貧血
    • 鐮狀β零地中海型貧血

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Acceleron Pharma, Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Baxter International, Inc.
  • Blue bird bio, Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Emmaus Life Science, Inc.
  • Global Blood Therapeutics, Inc.
  • Medunik USA, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
目錄
Product Code: OMR2021734

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, by Type (Medication (Hydroxyurea, L-Glutamine Oral Powder, Crizanlizumab, Voxelotor, Pain-relieving Medication, and others), Blood Transfusions and Bone-Marrow Transplant), by Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta-Thalassemia, and Sickle Beta-Zero Thalassemia), and Forecast 2019-2025

The global sickle cell disease treatment market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include includes growing innovation by the pharmaceutical companies and the support of governments of various countries. For instance, in November 2019, the US FDA announced the approval of Adakveo (Crizanlizumab-tmca) treatment with the aim to reduce the frequency of vaso-occlusive crisis in the sickle cell disease patients of age 16 year and above. In November 2019, FDA approved the use of Voxelotor (Oxbryta) for sickle cell disease treatment. Voxelotor is a polymerization inhibitor used to reduce the concentration of deoxygenated sickle hemoglobin helping in stopping the formation of polymer in red blood cells.

The growing number of sickle cell anemia disease owing to the increase in demand for sickle cell anemia treatment encouraging the sickle cell disease treatment market to grow. Sickle cell anemia is a disorder in which the red blood cell unable to transport a significant amount of oxygen to the organs. In this condition, the red blood cell becomes rigid, sticky and sickle in shape resulting in blockages of oxygen through red blood cells. The growing initiatives by the government toward sickle cell anemia treatment encouraging major companies in the innovation of multiple treatment options. This in turn supporting the growth of the market.

The global sickle cell disease treatmentmarket is segmented based on type and disease type. Based on drug type, the market is classified into medication, blood transfusions, and a bone-marrow transplant. Based on disease type, the market is classified into sickle cell anemia, sickle hemoglobin c disease, sickle beta-thalassemia and sickle beta-zero thalassemia.Geographically, the global sickle cell disease treatment market is classified into North America, Europe, Asia-Pacific and the Rest of the World.

The major players in the global sickle cell disease treatment market include Emmaus Life Science, Inc., Bristol-Myers Squibb Co., Pfizer, Inc., Global Blood Therapeutics, Inc., and Novartis AG. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe.For instance, in November 2016, Novartis AG announced its acquisition of Selexys Pharmaceuticals and the SelG1 antibody with the aim of reduced pain treatment for sickle cell disease patients in adults. This acquisition will strengthen Novartis's product portfolio of sickle cell disease treatment.

Research Methodology

The market study of the global sickle cell disease treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for drug manufacturers, suppliers and distributors, and government agenciesfor overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Sickle Cell Disease TreatmentMarket Research and Analysis by Type
  • Global Sickle Cell Disease TreatmentMarket Research and Analysis by Disease Type

The Report Covers:

  • Comprehensive research methodologies of the global sickle cell disease treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global sickle cell disease treatment market.
  • Insights about market determinants which are stimulating the global sickle cell disease treatmentmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Emmaus Life Science, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Bristol-Myers Squibb Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Pfizer, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Global Blood Therapeutics, Inc
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Novartis AG
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Sickle Cell Disease Treatment Market by Type
    • 5.1.1. Medication
      • 5.1.1.1. Hydroxyurea
      • 5.1.1.2. L-Glutamine Oral Powder
      • 5.1.1.3. Crizanlizumab
      • 5.1.1.4. Pain-Relieving Medications
      • 5.1.1.5. Voxelotor
    • 5.1.2. Blood Transfusions
    • 5.1.3. Bone-Marrow Transplant
  • 5.2. Global Sickle Cell Disease Market by Disease Type
    • 5.2.1. Sickle Cell Anemia
    • 5.2.2. Sickle Hemoglobin C Disease
    • 5.2.3. Sickle Beta Thalassemia
    • 5.2.4. Sickle Beta-Zero Thalassemia

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Acceleron Pharma, Inc.
  • 7.2. Arena Pharmaceuticals, Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Baxter International, Inc.
  • 7.5. Blue bird bio, Inc.
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Eli Lilly and Co.
  • 7.8. Emmaus Life Science, Inc.
  • 7.9. Global Blood Therapeutics, Inc.
  • 7.10. Medunik USA, Inc.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc.
  • 7.13. Sangamo Therapeutics, Inc.
  • 7.14. Sanofi S.A.

LIST OF TABLES

  • 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL BLOOD TRANSFUSIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL BONE-MARROW TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 6. GLOBAL SICKLE CELL ANEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL SICKLE HEMOGLOBIN C DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL SICKLE BETA THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL SICKLE BETA-ZERO THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BYTYPE, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 14. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 16. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 18. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 19. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 20. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BYTYPE, 2018-2025 ($ MILLION)
  • 21. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
  • 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)